Earl Martin Douglas sold $40k of ALLO
SVP, General Counsel at Allogene Therapeutics, Inc.. 22,900 shares at an average of $1.76, traded Feb 2, 2026, filed Feb 4, 2026.
Score components
- +15RoleOfficer
- +6Trade size$40k at market
- 0Share of holdings soldSold 3.9% of holdings
- +15Cluster6 insiders selling within 14 days
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001362155-26-000002, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Feb 2, 2026 | SOpen-market sale Common Stock | -22,900 | $1.76 | $40k | 564,948 | Feb 4, 2026 |
| Feb 2, 2026 | AGrant or award Stock Option (Right to buy)derivative | +539,072 | $0.00 | $0 | 539,072 | Feb 4, 2026 |
| Feb 2, 2026 | AGrant or award Restricted Stock Unitderivative | +152,480 | $0.00 | $0 | 152,480 | Feb 4, 2026 |
Related signals
Other insiders at Allogene Therapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 43Moderate | Allogene Therapeutics, Inc. | David D Chang President and CEO | $118k 47,763 shares | -1% | |
| 23Weak | Allogene Therapeutics, Inc. | Benjamin Machinas Beneski SVP, Chief Technical Officer | $12k 4,835 shares | -2% | |
| 23Weak | Allogene Therapeutics, Inc. | Benjamin Machinas Beneski SVP, Chief Technical Officer | $19k 7,132 shares | -3% | |
| 38Weak | Allogene Therapeutics, Inc. | Zachary Roberts EVP of R&D | $63k 35,700 shares | -6% | |
| 30Weak | Allogene Therapeutics, Inc. | Annie Yoshiyama SVP, Finance | $7,167 4,167 shares | -3% | |
| 43Moderate | Allogene Therapeutics, Inc. | Geoffrey M. Parker CHIEF FINANCIAL OFFICER | $42k 24,001 shares | -2% | |
| 51Moderate | Allogene Therapeutics, Inc. | David D Chang President and CEO | $171k 95,269 shares | -2% | |
| 30Weak | Allogene Therapeutics, Inc. | Benjamin Machinas Beneski SVP, Chief Technical Officer | $13k 7,549 shares | -3% | |
| 36Weak | Allogene Therapeutics, Inc. | Zachary Roberts EVP of R&D | $41k 26,269 shares | -4% | |
| 15Weak | ALLOsell Allogene Therapeutics, Inc. | Benjamin Machinas Beneski SVP, Chief Technical Officer | $959 786 shares | -0% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.